Dr Martens PLC
LSE:DOCS

Watchlist Manager
Dr Martens PLC Logo
Dr Martens PLC
LSE:DOCS
Watchlist
Price: 76.95 GBX 1.85% Market Closed
Market Cap: 744.2m GBX

Dr Martens PLC
Investor Relations

Dr. Martens Plc engages in the manufacture and sale of footwear products. The firm operates through three reporting segments: Europe, the Middle East and Africa (EMEA), Americas and Americas and Asia-Pacific (APAC). Its product categories include Originals, Fusion, Kids, Casual and Accessories. The Originals category comprises boots, shoes and loafers and also included within the Originals category is the Made in England range. The Fusion category comprises platform boots and shoes, sandals, heels and refined take downs of the Originals. Within the Kids category is the mini-me range, which includes Originals, Fusion and Casual collections. The company offers various accessories, such as shoe care, laces and socks, leather bags and small leather items. The company operates in over 60 countries globally, through a range of modes: directly operated stores and ecommerce sites, wholesale partners and distributors.

Show more
Loading
DOCS
FTSE All Share Index
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2026
Call Date
Nov 20, 2025
AI Summary
Q2 2026

Revenue Growth: Revenue rose slightly year-on-year to GBP 327.3 million, driven by improved full-price sales and reduced markdowns.

Profit Turnaround: Operating profit swung from a loss last year to a GBP 3.4 million profit, with adjusted EBIT benefiting from higher selling prices and lower costs.

Cash & Debt: Net bank debt reduced by GBP 33 million to GBP 154 million, and leverage ratios improved, positioning the company well for the year ahead.

Strategy Execution: Management remains on track with their strategic plan, focusing on reducing discount reliance, growing new product families, expanding in key markets, and simplifying operations.

Regional Performance: Americas and APAC performed strongly, while EMEA faced challenges due to a more cautious consumer and a deliberate reduction in discounts.

Tariff Mitigation: Actions taken will offset most U.S. tariff headwinds by FY '27, with about half the impact already mitigated in the current year.

Confident Outlook: Management reiterated confidence in full-year guidance and highlighted significant long-term growth opportunities.

Key Financials
Revenue
GBP 327.3 million
Operating Profit
GBP 3.4 million
Adjusted EBIT
GBP 3.4 million
Net Bank Debt
GBP 154 million
Total Debt (including leases)
GBP 302 million
Net Debt-to-EBITDA
2.1x
Dividend
0.85p
Americas DTC Retail Revenue
up 15.7%
DTC Full Price Revenue
up 6% year-on-year
Americas E-commerce Full Price Revenue
up 20%
DTC Shoes Pairs Sold
up 20%
Total Shoe Pairs Sold
up 33%
South Korea Revenue
up 30% year-on-year in H1
Earnings Call Recording
Other Earnings Calls
2026
2022

Management

Mr. Kenneth Wilson
CEO & Director
No Bio Available
Mr. Onyeije Ogueri Nwokorie
Chief Brand Officer
No Bio Available
Mr. Giles Wilson
CFO & Director
No Bio Available
Mr. Geert Peeters
Chief Operating Officer
No Bio Available
Graham Calder
Chief Technology Officer
No Bio Available
Ms. Bridget Jolliffe
Chief People Officer
No Bio Available
Ms. Emily Clare Reichwald
Chief Sustainability Officer
No Bio Available
Mr. Sean O'Neill
Chief Digital Officer
No Bio Available
Mr. Derek Chan
President of APAC
No Bio Available
Mr. Adam M. Meek
Chief Product Officer
No Bio Available

Contacts

Address
London
28 Jamestown Rd, Camden
Contacts
+443713842030.0
www.drmartensplc.com